Co-Diagnostics バランスシートの健全性
財務の健全性 基準チェック /66
Co-Diagnosticsの総株主資本は$16.0M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$21.5Mと$5.5Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$8.23m |
| エクイティ | US$16.04m |
| 負債合計 | US$5.46m |
| 総資産 | US$21.50m |
財務の健全性に関する最新情報
分析記事 • Feb 25
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Jun 14
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent updates
ナラティブの更新 • Oct 18
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Narrative Update on Co-Diagnostics Analysts have marginally increased their price target for Co-Diagnostics from $3.00 to $3.00, citing minimal changes in valuation inputs and updated financial forecasts as the rationale for this slight adjustment. What's in the News Announced development of a proprietary sample preparation instrument to streamline its point-of-care Co-Dx PCR Mycobacterium Tuberculosis Test.ナラティブの更新 • Oct 04
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Analysts have significantly lowered their price target for Co-Diagnostics from $10.00 to $3.00, citing revised fair value estimates and a reduced expectation for future earnings multiples. What's in the News Co-Diagnostics completed a $3.85 million Follow-on Equity Offering, issuing 9,619,000 shares of common stock at $0.40 per share in a registered direct offering.
新しいナラティブ • May 04
Co-Dx PCR Platform And FDA 510(K) Clearance Will Expand Market Reach
Advancements in PCR platform and manufacturing enhance commercialization, potentially increasing revenues and profit margins through scale efficiencies.分析記事 • Feb 25
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Jun 14
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • May 18
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
One thing we could say about the covering analyst on Co-Diagnostics, Inc. ( NASDAQ:CODX ) - they aren't optimistic...分析記事 • Apr 14
A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Key Insights Co-Diagnostics' estimated fair value is US$1.40 based on 2 Stage Free Cash Flow to Equity Current share...Seeking Alpha • Sep 07
Co-Diagnostics: Hold Thesis Remains Well Intact
Summary We reiterate the hold thesis on Co-Diagnostics following Q2 FY22 earnings. Covid-19 turnover continues to diminish for CODX whilst surging for rival test providers. Inventory levels for the company spiked year over year as the Omicron-led demand in testing faded. We've valued CODX at $3.24 suggesting shares are adequately priced by the market consensus. From the Portfolio Manager's Desk Having witnessed the rapid cooling of Omicron-led demand in Covid-19 diagnostics, the Sars-CoV-2 assay market is looking increasingly unattractive. Here revisit Co-Diagnostics, Inc. (CODX) a name that we are extremely familiar with having tracked the company across the entire span of the pandemic. We were buyers of the stock in January FY21 as a speculative position built around our core holdings in med-tech. We've since exited the position with a small loss, and believe impeding macro-headwinds remain for the company. With Covid-assay demand still diminishing, supplier inventory levels are likely at historically low levels, and the question is if they will seek to restore/repurchase inventory levels back to FY21 highs. The bulk of CODX's turnover is derived from Covid-19, so this is key to the investment debate for CODX looking ahead. Investment Thesis Summary Here we reiterate a hold rating on CODX with a $3.24 price target. With Covid-19 test revenue diminishing substantially in Q2 FY22 [whilst rival test makers revenue surged YoY] there is low predictability of the company's future cash flows by estimation. Valuations are supportive of a neutral view and forward looking earnings are marred by the fact Covid-19 test volumes will likely dwindle as time goes on. Although it has other innovations in the pipeline, the timing and timeline for these are fluid for now and there's no concrete launch dates. We need further clarity on how CODX intends to distribute its top-line ex-Covid. Rate hold price target $3.24. Co-Diagnostics' Q2 earnings illustrate headwinds CODX came in with a fairly weak set of numbers when compared to Q2 FY21. It clipped revenue of just $5 million ("mm"), an 81.6% YoY decrease from $27.4mm the year prior. The substantial tightening at the top line came as demand for CODX's Logix Smart Covid-19 test, that was developed in response to the pandemic [more on this later]. CODX also recognized a 54% YoY decline in sales to third parties of ~$75,000. Quarterly gross profit margin narrowed by 9 percentage points to 81.8% following the tighter revenue and unit volumes whilst fixed production costs made up a larger portion of revenues. Moving down the P&L, OPEX also narrowed by ~36% YoY to $8.3mm secondary to lower variable expenditures tied to sales volume. Quarterly operating loss came in at $4.17mm down from a profit of ~$11.8mm the year prior, again from the lower revenues and a $353,000 YoY gain in depreciation and amortization expense. Meanwhile R&D investment for the quarter came in 16.7% lower to $3.9mm from a relatively high base in Q2 FY21, and the company also bought back $2.6mm of its own stock. It brought this down to a quarterly net loss of ~$2.7mm or -$0.08/share, down from a $9.7mm/ $0.34 per share after-tax profit last year. CODX did still see profitability from CFFO during the quarter. In fact, for the 6-months to Q2 FY22, it printed $9.4mm [$0.28/share] in cash from operations. However, also noted is that it added $2.9mm stock based compensation expense to this, whereas accounts receivable value jumped $8.56mm during this time. Free cash flow ("FCF") has narrowed on a sequential basis for the company and came in at $1.15mm for the quarter and $25.2mm for the TTM. However, one point to note is that its TTM return on invested capital ("ROIC") has remained in the double digits at 24.2% last quarter and comfortably covers CODX's WACC hurdle of ~6.2% by ~4 turns. As seen in Exhibit 1, ROIC has remained consistently high whilst FCF is reinvested heavily back into the business. Exhibit 1. Quarterly FCF continues to decline whilst TTM ROIC remains buoyant, albeit tightening as well. This adds a bullish tilt to the risk/reward calculus and provides a solid bedrock for the company to continue seeing return on its investments looking ahead. Data: HB Insights, CODX SEC Filings Outlook weakened on lower test demand As have previously outlined, Covid-19 provided CODX with stellar revenue and earnings leverage that was reflected in its numbers at the time. Previously, we advocated that CODX's test volumes should remain high as there was currently no test to distinguish between influenza and Covid-19, a tailwind for assay kit producers. Management remain equally as optimistic, per language from CEO Dwight Egan on the Q2 earnings call: This dramatic shift [decrease] in testing behavior was widely felt across the diagnostics industry. Experts believe other waves of COVID variants are all, but inevitable. However, the timing and severity are impossible to predict with every new variant, including the possibility of immune escape as variants and sub-variants by for dominance. In the U.S. alone, we are still seeing around a 100,000 new COVID cases reported per day, over 6,000 COVID-related hospital admissions and nearly 400 deaths, all evidence to date points to a resilient mutable virus with no indication it will go away and that we will be living with it for years to come." Clearly, however, the Omicron-led demand for assay volumes has subsided and this is reflected in inventory values of both manufacturers and suppliers of the tests. We see evidence of this in CODX's numbers as its inventory value increased ~135% YoY in the second quarter to $4.7mm.財務状況分析
短期負債: CODXの 短期資産 ( $9.8M ) が 短期負債 ( $4.3M ) を超えています。
長期負債: CODXの短期資産 ( $9.8M ) が 長期負債 ( $1.2M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: CODXは負債がありません。
負債の削減: CODX 5 年前には負債がありませんでした。
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: CODXは、前回報告された フリーキャッシュフロー に基づいて3か月分の十分な キャッシュランウェイ を有していますが、その後追加の資本を調達しました。
キャッシュランウェイの予測: CODXフリーキャッシュフロー 推定値 に基づいて3か月間十分なキャッシュランウェイがあると予測されていますが、その後、追加の資本を調達しました。
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 12:15 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Co-Diagnostics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| James Sidoti | Sidoti & Company, LLC |